Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial

OBJECTIVE: Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. The efficacy and safety of axitinib in Japanese patients with metastatic renal cell carcinoma were evaluated. METHODS: A subgroup analysis was conducted in Japanese p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ueda, Takeshi, Uemura, Hirotsugu, Tomita, Yoshihiko, Tsukamoto, Taiji, Kanayama, Hiroomi, Shinohara, Nobuo, Tarazi, Jamal, Chen, Connie, Kim, Sinil, Ozono, Seiichiro, Naito, Seiji, Akaza, Hideyuki
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2013
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3664320/
https://ncbi.nlm.nih.gov/pubmed/23630366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyt054
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars